{"address1": "5750 Explorer Drive", "address2": "Suite 404", "city": "Mississauga", "state": "ON", "zip": "L4W 0A9", "country": "Canada", "phone": "905-602-5840", "website": "https://www.cipherpharma.com", "industry": "Drug Manufacturers\u2014Specialty & Generic", "industryDisp": "Drug Manufacturers\u2014Specialty & Generic", "sector": "Healthcare", "longBusinessSummary": "Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, which is indicated for the treatment of palpable or moderately thick hyperkeratotic actinic keratosis; Ozanex for the topical treatment of impetigo; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibriallation to sinus rhythm in adults; and Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with Acute Coronary Syndrome. The company's licensed products comprise Absorica, an oral retinoid indicated for the treatment of severe recalcitrant nodular acne; Lipofe indicated as adjunctive therapy to diet to reduce triglycerides in adult patients with severe hypertriglyceridemia; and Conzip, an opioid agonist indicated for the management of moderate to moderately severe chronic pain in adults. Its pipeline products include CF-101 for severe plaque psoriasis and rheumatoid arthritis; MOB-015, a topical formulation of terbinafine for treatment of onychomycosis; and DTR-001, a tattoo removal cream. Cipher Pharmaceuticals Inc. was founded in 2000 and is headquartered in Mississauga, Canada.", "companyOfficers": [{"maxAge": 1, "name": "Mr. Craig J. Mull", "title": "Interim CEO & Chairman", "fiscalYear": 2021, "totalPay": 96625, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Diane  Gajewczyk", "title": "VP of Scientific & Medical Affairs", "fiscalYear": 2021, "totalPay": 281099, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Bryan  Jacobs", "title": "Chief Financial Officer", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Emilio  Presti", "title": "Director of Sales & Marketing", "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1640908800, "maxAge": 86400, "priceHint": 4, "previousClose": 3.31, "open": 3.26, "dayLow": 3.18, "dayHigh": 3.26, "regularMarketPreviousClose": 3.31, "regularMarketOpen": 3.26, "regularMarketDayLow": 3.18, "regularMarketDayHigh": 3.26, "payoutRatio": 0.0, "beta": 1.046683, "trailingPE": 2.2957747, "forwardPE": 7.581395, "volume": 21429, "regularMarketVolume": 21429, "averageVolume": 14401, "averageVolume10days": 12780, "averageDailyVolume10Day": 12780, "bid": 3.26, "ask": 3.3, "bidSize": 0, "askSize": 0, "marketCap": 81752648, "fiftyTwoWeekLow": 2.0, "fiftyTwoWeekHigh": 4.07, "priceToSalesTrailing12Months": 3.9541788, "fiftyDayAverage": 3.476, "twoHundredDayAverage": 3.2922, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "CAD", "enterpriseValue": 54598600, "profitMargins": 1.2883201, "floatShares": 23568608, "sharesOutstanding": 25077500, "sharesShort": 39197, "sharesShortPriorMonth": 54448, "sharesShortPreviousMonthDate": 1680220800, "dateShortInterest": 1682640000, "sharesPercentSharesOut": 0.0016, "heldPercentInsiders": 0.42654, "heldPercentInstitutions": 0.002, "shortRatio": 2.39, "impliedSharesOutstanding": 0, "bookValue": 2.557, "priceToBook": 1.2749316, "lastFiscalYearEnd": 1672444800, "nextFiscalYearEnd": 1703980800, "mostRecentQuarter": 1672444800, "earningsQuarterlyGrowth": 6.004, "netIncomeToCommon": 26636000, "trailingEps": 1.42, "forwardEps": 0.43, "enterpriseToRevenue": 2.641, "enterpriseToEbitda": 4.569, "52WeekChange": 0.47767854, "SandP52WeekChange": 0.046755195, "exchange": "TOR", "quoteType": "EQUITY", "symbol": "CPH.TO", "underlyingSymbol": "CPH.TO", "shortName": "CIPHER PHARMACEUTICALS INC", "longName": "Cipher Pharmaceuticals Inc.", "firstTradeDateEpochUtc": 1083936600, "timeZoneFullName": "America/Toronto", "timeZoneShortName": "EDT", "uuid": "bf974aa9-7e98-34f9-9e9f-97cb76b5eb7c", "messageBoardId": "finmb_8201659", "gmtOffSetMilliseconds": -14400000, "currentPrice": 3.26, "targetHighPrice": 24.55, "targetLowPrice": 3.93, "targetMeanPrice": 10.89, "targetMedianPrice": 4.17, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 3, "totalCash": 28836000, "totalCashPerShare": 1.15, "ebitda": 11951000, "totalDebt": 428000, "quickRatio": 3.804, "currentRatio": 4.073, "totalRevenue": 20675000, "debtToEquity": 0.668, "revenuePerShare": 0.815, "returnOnAssets": 0.11012, "returnOnEquity": 0.51732, "grossProfits": 16683000, "freeCashflow": 4701250, "operatingCashflow": 10575000, "earningsGrowth": 6.16, "revenueGrowth": -0.161, "grossMargins": 0.80692, "ebitdaMargins": 0.57804, "operatingMargins": 0.53446, "financialCurrency": "USD", "trailingPegRatio": null}